CSPC Pharmaceutical (HKSE:01093) is a leading player of innovative, branded and common generic drugs in China, with major product lines including the "NBP" series, "Oulaining" series, and "Xuanning" series. It is also a key manufacturer of bulk drugs and principal products such as vitamin C, caffeine, and antibiotics. The company’s production facilities are mainly located in the city of Shijiazhuang in Hebei, China. Despite a relatively high level of valuation, we remain optimistic about the company’s growth potential in the next two to three years on the back of strong research & development capability and robust product pipelines.
From Value Partners (Trades, Portfolio)’ Classic Fund Second Quarter 2014 Commentary.
